SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
TELA reported third quarter ended September 30, 2026 results. The price and volatility reaction is pending.
TELAearnings

Earnings reactions, page 3

TELA Bio, Inc. (TELA) Q3 FY2026 earnings

November 11, 2026 · SharpeIQ Research Desk

Reported results

  • Revenue was $19.0 million in the third quarter of 2026, a decrease of 8% compared to $20.7 million in the third quarter of 2025.
  • GAAP gross profit was $12.3 million, or 64.9% of revenue, in the third quarter of 2026, compared to $14.0 million, or 67.5% of revenue, in the third quarter of 2025.
  • Non-GAAP adjusted gross margin was 71% in the third quarter of 2026 compared to 70% in the third quarter of 2025.
  • GAAP loss from operations was $7.3 million in the third quarter of 2026, compared to $7.6 million in the third quarter of 2025.
  • Non-GAAP Adjusted EBITDA loss was $3.4 million in the third quarter of 2026, an improvement of 39% compared to $5.7 million in the third quarter of 2025.
  • On a GAAP basis, net loss was $9.3 million, or $0.16 per common share, compared to $8.6 million, or $0.19 per common share, in the third quarter of 2025.
  • On a non-GAAP adjusted basis, net loss was $7.3 million, or $0.13 per common share, compared to $8.4 million, or $0.18 per common share, in the third quarter of 2025.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-10 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →